Home › Major Depressive Disorder › Pennsylvania
Major Depressive Disorder clinical trials in Pennsylvania
27 studies for Major Depressive Disorder are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Adams Clinical Philadelphia, Philadelphia
- Penn Medicine: University of Pennsylvania Health System, Philadelphia
- Suburban Research Associates, West Chester
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300Precision Depression Adalimumab Trial
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07845604Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- University of Pennsylvania, Philadelphia
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Pennsylvania - Perelman School of Medicine, Philadelphia
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT05850689A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Adams Clinical Philadelphia, Philadelphia
- Flourish Research Philadelphia, Philadelphia
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Allentown
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07065240Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
- University of Pennsylvania, Philadelphia
RecruitingEarly phase 1
Ages 25 to 65 · All sexes · Updated Sep 10, 2026 · NCT06788249Decoding and Modulating Affective Brain States
- University of Pennsylvania, Philadelphia
RecruitingMentions payment for participants
Ages 18 to 65 · All sexes · Updated Sep 3, 2026 · NCT05437705A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Allentown
- Draig Clinical Site, Media
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Pennsylvania Hospital, Philadelphia
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Media
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 14, 2026 · NCT07226232A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Adams Clinical Philadelphia, Philadelphia
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 10, 2026 · NCT07592689NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06963021A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Suburban Research Associates, Media
- Penn Medicine: University of Pennsylvania Health System, Philadelphia
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Lehigh Center For Clinical Research, Allentown
- Adams Clinical - Philadelphia, Philadelphia
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 3, 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Lehigh Center for Clinical Research, Allentown
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Aug 3, 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Lehigh Center for Clinical Research, Allentown
- Adams Clinical, Philadelphia
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments
- Bellefield Towers, Pittsburgh
Recruiting
Ages 18 to 55 · All sexes · Updated May 22, 2026 · NCT06976840Triage Survey for Psychiatry Research Eligibility
- Adams Clinical, Philadelphia, Philadelphia
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05800925A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Scranton Medical Institute, LLC, Moosic
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
- University of Pittsburgh, Pittsburgh
Recruiting
Ages 18 to 55 · All sexes · Updated Mar 4, 2026 · NCT05703256Taking Action for College Students
- Temple University, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated Dec 29, 2025 · NCT06700902Neurofeedback to Treat Depression - 2
- Center for Neuromodulation in Depression and Stress, Philadelphia
Recruiting
Ages 18 to 65 · All sexes · Updated Dec 4, 2025 · NCT07159061Study of ALTO-300 in MDD
- Site 216, Allentown
- Site 350, Media
- Site 352, Moosic
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 24, 2025 · NCT05922878From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.